Indication-Based Pricing
As more and more medicines come to market with multiple indications or the unrealised potential to treat multiple indications, the way we pay for those medicines becomes critical in making sure we can benefit from them. Indication-based pricing (IBP) permits price to vary according to indication and has been proposed to tackle this issue.
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022
Innovation in drug development is evolving at pace. Individual medicines are increasingly found to benefit patients in a range of indications….
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…
Indication-Based Pricing: Are We All Onboard?
12 May 2020
A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
1 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.